Dear Ms Bordier,
Concerning the Paxlovid market authorization application , please be certain to be on centralized procedure. Indeed it's compulsory for human medicines containing a new active substance to treat viral diseases.
I confirm that your treatment could be eligible to accelerate procedure.
Please finding the attached file all the document that you'll need.
If you have other question, I'll pleased to help you.
Best regards.
Mathilde Capelle
Regulatory Affairs at the EMA